BCLI: Brainstorm Cell Therapeutics, Inc. Consensus Target
Seamless delivery of biomaterials under strict temperature control ensures the stability of Brainstorm Cell (BCLI) operational processes. This price chart on GURU.Markets, serving as the primary valuation tool and reaching 20.71, highlights volatility amid fierce competition with industry behemoths. Meanwhile, the company is minimizing investment risks by developing partnerships with specialized centers to refine cellular treatment methodologies.
Analytical breakdowns for Brainstorm Cell Therapeutics, Inc. (BCLI)
- current price and projected stock value:
- market capitalization information:
- book value of equity indicators:
- issuer credit burden and liquidity indicators:
Debt to Equity Ratio Brainstorm Cell|BCLI - Long-Term Debt to Capital|Current Liabilities to Capital BrainStorm Cell Therapeutics Inc.|BCLI - Company Total Debt|Debts to Book Capitalization Brainstorm Cell|BCLI - Company Long-Term Debt|Company Short-Term Loans and Borrowings BrainStorm Cell Therapeutics|Immediate Liquidity brainstorm-cell.com
- financial results and valuation multiples details:
BCLI - Net Profit|Expected Profit Brainstorm Cell|BCLI - Price to Earnings Ratio|Future Price to Earnings Multiple Brainstorm Cell Therapeutics Inc.|BCLI - PEG Multiple|EV/EBITDA Multiple Brainstorm Cell|BCLI - Operating profit EBITDA|Net earnings per share for the last four quarters BrainStorm Cell Therapeutics|BCLI - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months brainstorm-cell.com|BCLI - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Brainstorm Cell
Summary company analytics:BCLI brainstorm-cell.com
This indicator represents the weighted average of target prices from leading investment houses, updated daily to eliminate analytical time lags. By analyzing the expected consensus value of the stock, investors gain a real-time assessment of expert reactions to the successes of Brainstorm Cell (BCLI) in developing cell therapies for neurodegenerative diseases and the effectiveness of their partnerships with specialized research centers.
Competitors of Brainstorm Cell
Price Target Chart BIIB (biogen.com)|Analyst Consensus Forecast NBIX (Neurocrine Biosciences, Inc.)|RGC - Consensus Target|AXSM - Price Target Chart|ACAD: Price Target Chart|XENE: Analyst Consensus Forecast|VKTX - Analyst Median Target|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|PRTA (Prothena Corporation PLC) - Analyst Consensus Forecast|Price Target Chart ALEC|Price Target Chart Annexon (ANNX)|OMER (omeros.com) - Fair Value Consensus|Analyst Consensus Forecast NGNE (Neurogene Corp)|Analyst Consensus Forecast AC Immune Inc ACIU|Voyager Therapeutics - Analyst Consensus Forecast|Analyst Median Target neumoratx.com NMRA|Scilex (SCLX) - Price Target Chart|Broker Consensus Forecast TVGN|Price Target Chart Alpha Cognition Inc|cogrx.com (CGTX) - Analyst Median Target|Consensus Target IKT (Inhibikase Therapeutics)|Analyst Forecast Prices SAVA|Price Target Chart Assertio ASRT|Coya Therapeutics Inc (COYA) - Average Forecast Price|VTGN - Price Target Chart|Fair Value Consensus OVID (Ovid Therapeutics Inc.)|Acumen Pharmaceuticals (ABOS) - Price Target Chart|Consensus Target cervomed.com|Consensus Target ATHE|CLNN: Fair Value Consensus|Analyst Consensus Forecast PEPG|Consensus Target jupiterneurosciences.com JUNS|Analyst Consensus Forecast RLMD (Relmada Therapeutics)|annovisbio.com (ANVS) - Average Forecast Price|GRCE - Price Target Chart|AIFF: Price Target Chart|anewmeds.com (KLTO) - Price Target Chart|NRSN (NeuroSense Therapeutics Ltd.) - Price Target Chart|RVPH (Reviva Pharmaceuticals) - Analyst Consensus Forecast|Price Target Chart MTVA|Analyst Consensus Forecast NRXS|Consensus Target heliusmedical.com HSDT|Price Target Chart Passage Bio PASG|Neuphoria Therapeutics, Inc. - Price Target Chart|Minerva Neurosciences - Analyst Consensus Forecast|Analyst Median Target athira.com ATHA|Addex Therapeutics Ltd (ADXN) - Price Target Chart|Broker Consensus Forecast ALZN|CYCN (Cyclerion Therapeutics Inc.) - Analyst Consensus Forecast|Average Forecast Price Protagenic PTIX|Consensus Target KTTA (Pasithea Therapeutics)|Analyst Consensus Forecast cortigent.com (CRGT)|Price Target Chart Avenue Therapeutics, Inc. ATXI|Fair Value Consensus CARA|CHRO - Price Target Chart|Average Forecast Price Eliem Therapeutics|ITCI: Analyst Consensus Forecast|LBPH (longboardpharma.com) - Price Target Chart|Price Target Chart Marinus Pharmaceuticals, Inc.|NKGN: Fair Value Consensus|Analyst Consensus Forecast NRBO|Analyst Consensus Forecast Sage Therapeutics Inc (SAGE)|Analyst Consensus Forecast SNPX (Synaptogenix, Inc.)|Analyst Median Target trevena.com (TRVN)|VIGL - Price Target Chart|WENA (Anew Medical Inc.) - Broker Consensus Forecast|Cerevel (CERE) - Price Target Chart
